HomeCompareTALS vs EPRT

TALS vs EPRT: Dividend Comparison 2026

TALS yields 55.51% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TALS wins by $458.2K in total portfolio value
10 years
TALS
TALS
● Live price
55.51%
Share price
$2.72
Annual div
$1.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$521.6K
Annual income
$114,803.66
Full TALS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — TALS vs EPRT

📍 TALS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTALSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TALS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TALS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TALS
Annual income on $10K today (after 15% tax)
$4,718.75/yr
After 10yr DRIP, annual income (after tax)
$97,583.11/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, TALS beats the other by $86,668.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TALS + EPRT for your $10,000?

TALS: 50%EPRT: 50%
100% EPRT50/50100% TALS
Portfolio after 10yr
$292.5K
Annual income
$63,822.19/yr
Blended yield
21.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

TALS
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
5.6
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TALS buys
0
EPRT buys
0
No recent congressional trades found for TALS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTALSEPRT
Forward yield55.51%3.92%
Annual dividend / share$1.51$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$521.6K$63.4K
Annual income after 10y$114,803.66$12,840.73
Total dividends collected$425.9K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: TALS vs EPRT ($10,000, DRIP)

YearTALS PortfolioTALS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$16,251$5,551.47$11,205$505.18+$5.0KTALS
2$25,821$8,431.73$12,672$682.46+$13.1KTALS
3$40,148$12,520.17$14,490$930.48+$25.7KTALS
4$61,153$18,193.88$16,786$1,282.69+$44.4KTALS
5$91,333$25,899.34$19,753$1,791.56+$71.6KTALS
6$133,877$36,150.61$23,677$2,541.64+$110.2KTALS
7$192,771$49,523.37$29,008$3,672.99+$163.8KTALS
8$272,910$66,644.47$36,463$5,425.08+$236.4KTALS
9$380,191$88,177.34$47,238$8,221.57+$333.0KTALS
10$521,608$114,803.66$63,385$12,840.73+$458.2KTALS

TALS vs EPRT: Complete Analysis 2026

TALSStock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Full TALS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this TALS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TALS vs SCHDTALS vs JEPITALS vs OTALS vs KOTALS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.